Linking Phenotypes and Modes of Action Through High-Content Screen Fingerprints
Abstract
High-content screening (HCS) is a powerful technique for monitoring phenotypic responses to treatments on a cellular and subcellular level. Cellular phenotypes can be characterized by multivariate image readouts such as shape, intensity, or texture. The corresponding feature vectors can thus be defined as HCS fingerprints that serve as a powerful biological compound descriptor. Therefore, clustering or classification of HCS fingerprints across compound treatments allows for the identification of similarities in protein targets or pathways. We developed an HCS-based profiling panel that serves as basis for characterizing the mode of action of compounds. This panel measures phenotypic effects in six different compartments of U-2OS cells, namely the nucleus, the cytoplasm, the endoplasmic reticulum, the Golgi apparatus, and the cytoskeleton. We profiled a set of 2,725 well-annotated compounds and clustered their corresponding HCS fingerprints to establish links between predominant cellular phenotypes and cellular processes and protein targets. We found various different clusters enriched for individual targets (e.g., HDAC, HSP90, TOP1, HMGCR, TUB), signaling pathways (e.g., PIK3/AKT/mTOR), or gene sets associated with diseases (e.g., psoriasis, leukemia). Based on this clustering we were able to identify novel compound-target associations for selected compounds such as a submicromolar inhibitory activity of Silmitasertib (a casein kinase inhibitor) on PI3K and mTOR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Z-score oversimplifies interpretation and fails to capture changes in the modality of population-level feature distributions or subpopulations with different responses.
“While the Z-score is commonly used to quantify phenotypic differences between treatment and control conditions23,28, it oversimplifies interpretation and will fail to capture changes in the modality of population-level feature distributions or subpopulations with different responses11.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [23]
Using multiple marker panels allows surveying a broader spectrum of features and can reduce the risk of bleed-through between fluorescent channels.
“Using multiple marker panels19,23 allows for surveying a broader spectrum of features and can reduce the risk of bleed-through between fluorescent channels depending on the assay design.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [23]
The citation lists haven’t been fetched yet
References 50 · Cited by 76
- Authors
- Reisen, F., Sauty de Chalon, A., Pfeifer, M., Zhang, X., Gabriel, D., & Selzer, P.
- Affiliations
- Novartis (Switzerland) (CH)
- Novartis Institutes for BioMedical Research
- Venue
- ASSAY and Drug Development Technologies
- Publisher
- SAGE Publications
- Published
- 2015-09
- Volume
- 13
- Issue
- 7
- Pages
- 415-427
- ISSN
- 1540-658X (ISSN-L)
- 1557-8127
- OpenAlex
- W1185588434
- Cited by
- 76
- References
- 50
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 11 · 2018: 9 · 2017: 8 · 2016: 9
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Assay and Drug Development Technologies (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Cell Image Analysis Techniques
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Keywords
- mechanism of action, compound profiling, cell phenotype, U2OS cells, PI3K/AKT/mTOR pathway, silmitasertib, histone deacetylase inhibitors, Hsp90 inhibitors, topoisomerase I inhibitor, HMGCR inhibitors, tubulin polymerization inhibitors, drug repurposing
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Humans, Phenotype, Tubulin Modulators, Histone Deacetylase Inhibitors, High-Throughput Screening Assays, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review